NCT06666491View on ClinicalTrials.gov

An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

May 25, 2026

Study Completion Date

May 25, 2026

Conditions
Malaria, Vivax
Interventions
DRUG

Tafenoquine

A single dose of TQ will be administered orally on Day 1 or Day 2.

DRUG

Primaquine

A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).

DRUG

Chloroquine

A single dose of CQ will be administered orally, daily, on Days 1 to 3.

Trial Locations (4)

380008

RECRUITING

GSK Investigational Site, Ahmedabad

395004

RECRUITING

GSK Investigational Site, Surat

400012

RECRUITING

GSK Investigational Site, Mumbai

700073

RECRUITING

GSK Investigational Site, Kolkata

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06666491 - An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older | Biotech Hunter | Biotech Hunter